The director of START in Spain, Emiliano Calvo, the vice president of the Investigational Therapeutics in Oncological Sciences of INTHEOS foundation, Mercedes Sánchez-Pérez, and the rector and manager of CEU San Pablo University, Rosa Visiedo and Carmen García de Elías, respectively, have signed the collaboration agreement for the creation of the INTHEOS-START-CEU Chair in molecular cancer therapy, attached to the Faculty of Medicine of CEU San Pablo University.
This new Chair will promote research in the area of new cancer treatments, as well as the molecular underpinnings of its origins and how well it responds to these new treatments. More specifically, by leveraging synergistic research projects, the Chair will try both to identify therapeutic vulnerabilities in cancer and mechanisms of resistance for treatments aimed at molecular targets, as well as to create therapeutic tools including biological and chemical compounds. Moreover, this Chair will support the propagation of new knowledge in the field of Medical and Translational Oncology by means of teaching, scientific conferences and publications.
The Chair belongs to the Faculty of Medicine of CEU San Pablo University and is co-directed by Dr. Emiliano Calvo, Professor at CEU San Pablo, and Dr. Alberto Ocaña, Director of Translational Research at START Spain. The coordinator of the Chair will be Professor Maria M. Escribese Alonso.
In its commitment to research as a basis for academic excellence, CEU San Pablo University has several research chairs in different areas. This new one brings it to a total of 12 chairs promoted by the Vice-Rectorate for Research, Transfer and Scientific Dissemination of the University that are maintained with various companies in the sector.
About INTHEOS Foundation
The Fundación INTHEOS -Investigational Therapeutics in Oncological Sciences- is a private non-profit institution, established in 2010 by a prestigious medical team in the field of biomedical research in oncology. Its mission is to bring the latest advances in cancer treatment and research based on personalized medicine to oncology patients.
About START Madrid
South Texas Accelerated Research Therapeutics (START),a global leader in Phase I clinical trials, aims to accelerate the development of new drugs used in the prevention and treatment of cancer and to offer the patients access to the new therapies when the traditional ones are not effective.